האגודה למלחמה בסרטן - ביטאון לעובדי בריאות בנושא מחלת הסרטן והשלכותיה - גיליון 20 אוקטובר 2014
ביטאון לעובדי בריאות בנושא מחלת הסרטן והשלכותיה במה
30. Daly MB, Axilbund JE, Buys S, et al. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010 May;8(5):562–94. 31. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7/ 32. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group.J Clin Oncol 2004 Mar 15;22(6):1055-62. Epub 2004 Feb 23. 33. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000 Jun 10;355:2015-20. 34. Domchek SM, Fiebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar;7(3):223-9. 35. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA. 2010 Sep 1;304(9):967-75. 36. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23;346(21):1616-22. Epub 2002 May 20. 37. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005 Oct 20;23(30):7491-6. 38. King MC, Wieand HS, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: A genomic resequencing study in the NSABP-P1 Breast Cancer Prevention Trial (BCPT). JAMA. 2001 Nov 14;286(18):2251-6. 39. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62. 40. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328-35,2004 41. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 1;118(9):2281-4. 42. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006 Jul 13;355(2):125-37. 43. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. 44. National Institute for Health and Care Excellence (NICE). Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE guidelines [CG164]. 2013 Jun; London: NICE. Available from: http://guidance.nice.org.uk/CG164/ NICEGuidance/pdf/English Ingle JN, Liu M, Wickerham DL, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov. 2013 Jul;3(7):812-25. Epub 2013 Jun 13. 45. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007 Dec;114(12):1500-9. Epub 2007 Sep 27.
46. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008 Sep 1;26(25):4160–5. 47. Kauff ND, Satagopan JM, Robson ME, et al. Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med. 2000 May 23;346(21):1609-15. Epub 2002 May 20. 48. Finch A, Beiner M, Lubinski J, et al. Salpingo- oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12;296(2):185-92. 49. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993 May 1;71(9):2751-5. 50. Eisen A, Lubinski J, Gronwald J, et al. Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008 Oct 1;100(19):1361- 7. 51. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006 Oct;30(10):1222-30. 52. Laki F, Kirova YM, This P, et al. Prophylactic salpingo- oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 2007 May 1;109(9):1784-90. 53. Movahedi-Lankarani S, Baker PM, Gilks B, Soslow RA, Oliva E. Protocol for the examination of specimens from patients with carcinoma of the ovary [Internet]. Revision Ovary 18.104.22.168. Based on AJCC/UICC TNM, 7th Edition. 2009 Oct. College of American Pathologists (CAP). Available from: http:// www.cap.org/apps/docs/committees/cancer/cancer_ protocols/2009/Ovary_09protocol.pdf 54. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010 Aug;46(12):2275-84. Epub 2010 May 27. 55. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998 Aug 13;339(7):424-8. 56. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 26;345(4):235-40.
13. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991 Feb;48(2):232-42. 14. van Harssel JJ, van Roozendaal CE, Detisch Y, et al. Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. Fam Cancer. 2010 Jun;9(2):193-201. 15. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol. 2006 Feb 1;24(4):707-15. 16. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008 Jul;45(7):425-31. 17. Stadler ZK, Saloustros E, Hansen NA, et al. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Res Treat. 2010 Sep;123(2):581-5. 18. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997 Mar;60(3):496-504. 19. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91:1241-7. 20. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676-89. 21. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088-90. 22. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 222 studies. Am J Hum Genet. 2003 May;72(5):1117–30. Epub 2003 Apr 3. 23. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006 Dec;98(23):1694–706. 24. Simchoni S, Friedman E, Kaufman B, et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U.S.A. 2006 Mar 7;103(10):3770-4. Epub 2006 Feb 28. 25. National Comprehensive Cancer Network (NCCN). NCCN guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian [Internet]. Version 1.2014. 2014; NCCN. Available from: http:// www.nccn.org/professionals/physiciangls/pdf/ geneticsscreening.pdf 26. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Cancer surveillance based in imaging techniques in carrier of BRCA1/2 gene mutations: a systematic review. Br J Radiol. 2008 Mar;81(963):172-9. 27. Robson M,Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007 Jul 12;357(2)154-62. 28. Riedl CC, Ponhold L, Flöry D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res. 2007 Oct 15;13(20):6144-52. 29. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011 May 1;29(13):1664–9. Epub 2011 Mar 28.
Made with FlippingBook - Online catalogs